loading page

Cancer Predisposition Syndromes in Children: Who, How and When Should Genetic Studies Be Considered?
  • +6
  • Mónica Camacho,
  • Marta Villa,
  • Sara Álvarez de Andres,
  • Bárbara Rivera,
  • Paula Vázquez,
  • Patricia Letón,
  • Laura Martín,
  • Marta Pilar Osuna-Marco,
  • Blanca López-Ibor
Mónica Camacho
Hospital Universitario HM Monteprincipe

Corresponding Author:monica.camachoarias@gmail.com

Author Profile
Marta Villa
Hospital Universitario HM Monteprincipe
Author Profile
Sara Álvarez de Andres
NIMGenetics Genomica y Medicina SL
Author Profile
Bárbara Rivera
Institut d'Investigacio Biomedica de Bellvitge
Author Profile
Paula Vázquez
Hospital Universitario HM Monteprincipe
Author Profile
Patricia Letón
Hospital Universitario HM Monteprincipe
Author Profile
Laura Martín
Hospital Universitario HM Monteprincipe
Author Profile
Marta Pilar Osuna-Marco
Hospital Universitario HM Monteprincipe
Author Profile
Blanca López-Ibor
Hospital Universitario HM Monteprincipe
Author Profile

Abstract

Early detection of cancer predisposition syndromes (CPS) is crucial to determine optimal treatments and follow-up, and to provide appropriate genetic counseling. This study outlines an approach in a pediatric oncology unit, where 50 randomly selected patients underwent clinical assessment, leading to 44 eligible for genetic testing. We identified 3 pathogenic or likely pathogenic variants in genes associated with CPS and 6 Variants of Uncertain Significance (VUS) potentially associated with cancer development. We emphasize the importance of a thorough and accurate collection of family history and physical examination data and the full coordination between pediatric oncologists and geneticists.